USPTO 2015–2025 USPTO PatentsView US Corporation

Celldex Therapeutics, Inc.

USPTO PatentsView assignee record - 34 granted patents across 10 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled by PlainPatent · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

14.8

Avg claims per patent

+20%

5-year grant velocity

The verdict

According to USPTO PatentsView, Celldex ranks #9,226 of 50,000 tracked US assignees by granted-patent volume, with 34 patents across 10 technology areas.

#9,226
of 50,000 US assignees by volume: Top 47%
by Innovation Score (36.1/100): 14.8
avg claims per patent: +20%
grant velocity, last 5 yrs

Portfolio overview

Celldex Therapeutics, Inc. has been granted 34 US utility patents between 2015 and 2025, placing Celldex Therapeutics, Inc. at #9,226 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.8 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Celldex Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Celldex sits between Canary Medical Inc. (34 patents, rank #9,228) and Consolidated Metco, Inc. (34 patents, rank #9,236) - the closest US assignees by grant volume. The composite Innovation Score of 36.1/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 18 grants, compared with 15 in the 2015–2019 window, a +20% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Celldex Therapeutics, Inc.'s 14.8 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 10 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Canary Medical

34
Canon Information…

34
Canrig Robotic AS

34
Carebay Europe

34
Chien Luen Indust…

34
Clearone

34
Computime

34
Consolidated Metco

34
Celldex Therapeut… ◀

34

What this shows Celldex holds 34 patents at rank #9,232, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Celldex

By rank, the assignees closest to #9,232 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Celldex's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Celldex, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (36 here).

DWS S.r.l. 36 Elpis Technologies Inc. 36 Brunson Instrument Company 36 Germans Boada, S.a. 36

Celldex's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 47% higher than 53% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Celldex Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	8.8%
2016	3	8.8%
2017	5	14.7%
2019	4	11.8%
2020	7	20.6%
2021	3	8.8%
2022	2	5.9%
2023	1	2.9%
2024	5	14.7%
2025partial year	1	2.9%

Which technologies does Celldex Therapeutics, Inc. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 32

C07K - PEPTIDES 32

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 32

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 11

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 6

C12Y - ENZYMES 5

Y02A - TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE 2

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 1

A01K - ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS 1

A01N - PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS 1

Top 10 of 10 technology areas

Grant record at a glance

Portfolio Volume 34 grants

CPC subclasses 10

Avg. claims / grant 14.8

Velocity +20%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#9,226

of 50,000 tracked assignees

Innovation Score

36.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Celldex Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Celldex Therapeutics, Inc. ranks #9,226 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Celldex Therapeutics, Inc. hold?

Celldex Therapeutics, Inc. holds 34 US utility patents granted between 2015 and 2025, spanning 10 technology areas.

What is Celldex Therapeutics, Inc.'s Innovation Score?

Celldex Therapeutics, Inc. has an Innovation Score of 36.1 out of 100 (top 47% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Celldex Therapeutics, Inc. focus on?

Celldex Therapeutics, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 32 patents. Grants appear in 10 CPC subclasses total.

Is Celldex Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Celldex Therapeutics, Inc.'s recent grant velocity is +20% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Celldex Therapeutics, Inc.'s patents?

Celldex Therapeutics, Inc.'s patents average 14.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Celldex Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Celldex's 34 grants land it in the top 47% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Celldex ranks #9,226 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.